Page last updated: 2024-09-03

muramylnac-ala-isogln-lys-tripeptide and interleukin-8

muramylnac-ala-isogln-lys-tripeptide has been researched along with interleukin-8 in 1 studies

Compound Research Comparison

Studies
(muramylnac-ala-isogln-lys-tripeptide)
Trials
(muramylnac-ala-isogln-lys-tripeptide)
Recent Studies (post-2010)
(muramylnac-ala-isogln-lys-tripeptide)
Studies
(interleukin-8)
Trials
(interleukin-8)
Recent Studies (post-2010) (interleukin-8)
504123,5231,1679,990

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ghosh, S; Hervé, M; Hunt, KA; Playford, RJ; van Heel, DA1

Other Studies

1 other study(ies) available for muramylnac-ala-isogln-lys-tripeptide and interleukin-8

ArticleYear
Normal responses to specific NOD1-activating peptidoglycan agonists in the presence of the NOD2 frameshift and other mutations in Crohn's disease.
    European journal of immunology, 2006, Volume: 36, Issue:6

    Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adaptor Proteins, Signal Transducing; Crohn Disease; Enzyme-Linked Immunosorbent Assay; Genotype; Humans; Interleukin-1; Interleukin-8; Intracellular Signaling Peptides and Proteins; Lipopolysaccharides; Nod1 Signaling Adaptor Protein; Nod2 Signaling Adaptor Protein; Peptidoglycan; Tumor Necrosis Factor-alpha

2006